Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Instruments and Supplies

AtriCure, Inc. develops, manufactures, and sells surgical devices to create precise lesions in soft tissues. The Company offers bipolar ablation systems uses by cardiothoracic surgeons as a standard treatment alternative to create lesions in heart tissue to block the abnormal electrical impulses that cause atrial fibrillation. AtriCure serves customers worldwide.
Website: atricure.com



Growth: Good revenue growth rate 14.9%, there is slowdown compared to average historical growth rates 15.8%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is positive, +4.7%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 208.6% higher than minimum and 4.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.5x by EV / Sales multiple , the company can be 48.8% overvalued

Insiders: For the last 3 months insiders sold company shares on $1.6 mln (-0.063% of cap.)

Key Financials (Download financials)

Ticker: ATRC
Share price, USD:  (-4.3%)61.28
year average price 40.54  


year start price 32.05 2025-11-07

min close price 25.86 2026-06-02

max close price 64.02 2026-11-04

current price 61.28 2026-11-06
Common stocks: 48 893 000

Dividend Yield:  0.0%
FCF Yield LTM: 0.8%
EV / LTM EBITDA: 103.6x
EV / EBITDA annualized: 90.7x
Last revenue growth (y/y):  +14.9%
Last growth of EBITDA (y/y):  +100.0%
Historical revenue growth:  +15.8%
Historical growth of EBITDA:  0.0%
EV / Sales: 4.9x
Margin (EBITDA LTM / Revenue): 4.7%
Fundamental value created in LTM:
Market Cap ($m): 2 996
Net Debt ($m): -94
EV (Enterprise Value): 2 902
Price to Book: 6.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-14seekingalpha.com

AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-24zacks.com

Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year?

2025-12-08zacks.com

Are Medical Stocks Lagging AtriCure (ATRC) This Year?

2025-11-29fool.com

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

2025-11-20zacks.com

Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?

2025-11-10seekingalpha.com

AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript

2025-11-06zacks.com

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)

2025-11-04zacks.com

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

2025-10-29seekingalpha.com

AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript

2025-10-29zacks.com

Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-30 2024-07-31 2024-05-02 2023-11-02 2023-07-26 2023-05-03 2022-11-02
acceptedDate 2025-10-30 12:21:59 2025-07-30 12:34:04 2025-02-14 13:39:56 2024-10-30 11:49:04 2024-07-31 11:39:45 2024-05-02 11:15:36 2024-02-16 14:10:25 2023-11-02 12:17:44 2023-07-26 13:42:17 2023-05-03 12:32:32 2023-02-22 13:07:54 2022-11-02 13:56:39 2022-02-17 15:27:04 2021-02-26 13:29:30
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 134M 136M 465M 116M 116M 109M 399M 98M 101M 93M 330M 83M 274M 207M
costOfRevenue 33M 35M 118M 29M 30M 28M 99M 24M 24M 24M 84M 22M 68M 57M
grossProfit 101M 101M 348M 87M 86M 81M 300M 74M 77M 70M 246M 62M 206M 149M
grossProfitRatio 0.755 0.745 0.749 0.74 0.74 0.752 0.764 0.745 0.741
researchAndDevelopmentExpenses 23M 29M 96M 21M 20M 20M 74M 20M 17M 15M 57M 15M 49M 43M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 78M 78M 291M 73M 74M 72M 253M 62M 64M 60M 231M 57M 205M 150M
otherExpenses 0 0 0 0 28 000 -82 000 0 -919 000 -881 000 -616 000 0 0 -103M 0
operatingExpenses 101M 108M 388M 94M 93M 91M 327M 82M 81M 75M 289M 72M 151M 194M
costAndExpenses 134M 142M 505M 123M 123M 120M 426M 106M 105M 99M 373M 94M 219M 251M
interestIncome 2M 941 000 4M 1M 997 000 952 000 4M 915 000 961 000 875 000 2M 370 000 466 000 1M
interestExpense 3M 1M 6M 2M 2M 2M 7M -2M -2M -2M 5M 1M 5M 5M
depreciationAndAmortization 5M 5M 19M 5M 5M 4M 15M 4M 4M 3M 12M 3M 10M 10M
ebitda 8M 732 000 -19M -936 000 -2M -6M -8M -8M -4M -6M -30M -8M 66M -34M
ebitdaratio 0.059 0.005 -0.008 -0.023 -0.059 -0.082 -0.041 -0.062 -0.095
operatingIncome 208 000 -6M -40M -7M -7M -11M -27M -8M -4M -6M -43M -11M 55M -44M
operatingIncomeRatio 0.002 -0.045 -0.064 -0.062 -0.1 -0.082 -0.041 -0.062 -0.129
totalOtherIncomeExpensesNet -294 000 263 000 -4M -126 000 -587 000 -2M -3M -919 000 -881 000 -616 000 -4M -2M -5M -4M
incomeBeforeTax -86 000 -6M -44M -8M -8M -13M -30M -9M -5M -6M -46M -12M 50M -48M
incomeBeforeTaxRatio -0.001 -0.044 -0.065 -0.067 -0.12 -0.092 -0.05 -0.068 -0.147
incomeTaxExpense 181 000 261 000 1M 322 000 253 000 183 000 591 000 47 000 93 000 78 000 268 000 46 000 188 000 114 000
netIncome -267 000 -6M -45M -8M -8M -13M -30M -9M -5M -6M -46M -12M 50M -48M
netIncomeRatio -0.002 -0.045 -0.068 -0.069 -0.122 -0.092 -0.051 -0.069 -0.147
eps -0.01 -0.13 -0.95 -0.17 -0.17 -0.28 -0.66 -0.2 -0.11 -0.14 -1.02 -0.27 1.11 -1.14
epsdiluted -0.01 -0.13 -0.17 -0.17 -0.28 -0.2 -0.11 -0.14 -0.27
weightedAverageShsOut 48M 48M 47M 47M 47M 47M 46M 46M 46M 46M 46M 46M 45M 42M
weightedAverageShsOutDil 48M 48M 47M 47M 47M 47M 46M 46M 46M 46M 46M 46M 46M 42M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-16 2023-02-22 2022-02-17 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -2M -3M -3M -4M -4M
ebit -37M -23M -41M 55M -43M
nonOperatingIncomeExcludingInterest -3M -4M -1M -100 000 -1M
netIncomeFromContinuingOperations -45M -30M -46M 50M -48M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -45M -30M -46M 50M -48M
epsDiluted -0.95 -0.66 -1.02 1.09 -1.14

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-30 2024-07-31 2024-05-02 2023-11-02 2023-07-26 2023-05-03 2022-11-02
acceptedDate 2025-10-30 12:21:59 2025-07-30 12:34:04 2025-02-14 13:39:56 2024-10-30 11:49:04 2024-07-31 11:39:45 2024-05-02 11:15:36 2024-02-16 14:10:25 2023-11-02 12:17:44 2023-07-26 13:42:17 2023-05-03 12:32:32 2023-02-22 13:07:54 2022-11-02 13:56:39 2022-02-17 15:27:04 2021-02-26 13:29:30
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 148M 118M 123M 130M 106M 65M 84M 81M 67M 77M 58M 49M 44M 42M
shortTermInvestments 0 0 0 0 8M 41M 53M 52M 60M 59M 63M 74M 75M 202M
cashAndShortTermInvestments 148M 118M 123M 130M 114M 106M 137M 133M 127M 136M 121M 123M 119M 244M
netReceivables 63M 66M 60M 55M 56M 55M 53M 52M 48M 46M 43M 41M 33M 23M
inventory 79M 76M 75M 77M 74M 72M 68M 62M 55M 49M 46M 44M 39M 35M
otherCurrentAssets 11M 11M 9M 7M 10M 12M 9M 6M 7M 8M 0 4M 0 0
totalCurrentAssets 301M 271M 268M 269M 253M 245M 266M 253M 238M 238M 215M 212M 196M 307M
propertyPlantEquipmentNet 46M 48M 47M 50M 46M 46M 47M 45M 45M 44M 43M 43M 36M 30M
goodwill 235M 235M 235M 235M 235M 235M 235M 235M 235M 235M 235M 235M 235M 235M
intangibleAssets 50M 52M 56M 58M 60M 62M 64M 66M 67M 39M 39M 40M 43M 128M
goodwillAndIntangibleAssets 285M 287M 291M 293M 295M 297M 299M 300M 302M 273M 274M 275M 278M 363M
longTermInvestments 0 0 0 0 0 0 0 0 8M 26M 52M 51M 104M 14M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 3M 3M 3M 3M 3M 2M 2M 2M 2M 2M 829 000 955 000 440 000
totalNonCurrentAssets 334M 338M 342M 346M 344M 346M 348M 348M 356M 345M 370M 370M 419M 408M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 635M 609M 609M 615M 597M 592M 614M 600M 594M 583M 585M 582M 615M 715M
accountPayables 25M 26M 25M 32M 27M 29M 27M 25M 24M 24M 20M 24M 19M 13M
shortTermDebt 3M 3M 3M 5M 5M 3M 3M 21M 16M 11M 3M 2M 0 7M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 2M 1M 1M
deferredRevenue 0 0 0 29M -59M 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 49M 40M 46M 8M 29M 30M 3M 37M 32M 28M 3M 31M 33M 9M
totalCurrentLiabilities 78M 69M 73M 74M 61M 61M 75M 83M 71M 62M 58M 58M 56M 49M
longTermDebt 74M 74M 62M 74M 73M 62M 61M 54M 59M 65M 57M 73M 60M 53M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 7M 1M 1M 1M 1M 12M 1M 1M 1M 1M 1M 48M 1M 187M
totalNonCurrentLiabilities 81M 76M 75M 76M 74M 74M 73M 55M 60M 66M 70M 74M 75M 253M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 15M 15M 12M 15M 13M 11M 11M 12M 12M 13M 14M 15M 16M 14M
totalLiabilities 159M 144M 148M 150M 135M 135M 148M 137M 132M 128M 129M 132M 132M 302M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 50 000 50 000 49 000 49 000 49 000 48 000 48 000 47 000 47 000 47 000 47 000 46 000 46 000 45 000
retainedEarnings -415M -415M -402M -386M -378M -370M -357M -347M -338M -333M -327M -322M -280M -330M
accumulatedOtherComprehensiveIncomeLoss 573 000 749 000 -1M -147 000 -569 000 -697 000 -993 000 -2M -3M -3M -4M -5M -948 000 312 000
othertotalStockholdersEquity 891M 878M 851M 841M 827M 812M 803M 791M 778M
totalStockholdersEquity 477M 464M 461M 465M 462M 456M 466M 463M 462M 455M 457M 450M 484M 412M
totalEquity 477M 464M 461M 465M 462M 456M 466M 463M 462M 455M 457M 450M 484M 412M
totalLiabilitiesAndStockholdersEquity 635M 609M 615M 597M 592M 600M 594M 583M 582M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 635M 609M 609M 615M 597M 592M 614M 600M 594M 583M 585M 582M 615M 715M
totalInvestments 0 0 0 0 8M 41M 53M 52M 67M 84M 115M 125M 180M 216M
totalDebt 77M 77M 77M 77M 75M 75M 74M 74M 75M 75M 75M 75M 76M 74M
netDebt -71M -41M -46M -53M -31M 10M -10M -6M 8M -2M 16M 26M 32M 32M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-16 2023-02-22 2022-02-17 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 60M 53M 43M 33M 23M
otherReceivables 0 0 0 0 0
prepaids 0 0 5M 5M 4M
totalPayables 25M 27M 20M 19M 13M
otherPayables 0 0 0 0 0
accruedExpenses 0 42M 30M 3M 19M
capitalLeaseObligationsCurrent 0 0 2M 2M 2M
capitalLeaseObligationsNonCurrent 12M 11M 12M 14M 12M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 864M 824M 787M 765M 742M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC ATRC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-30 2024-07-31 2024-05-02 2023-11-02 2023-07-26 2023-05-03 2022-11-02
acceptedDate 2025-10-30 12:21:59 2025-07-30 12:34:04 2025-02-14 13:39:56 2024-10-30 11:49:04 2024-07-31 11:39:45 2024-05-02 11:15:36 2024-02-16 14:10:25 2023-11-02 12:17:44 2023-07-26 13:42:17 2023-05-03 12:32:32 2023-02-22 13:07:54 2022-11-02 13:56:39 2022-02-17 15:27:04 2021-02-26 13:29:30
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -267 000 -6M 0 -8M -8M -13M -30M -9M -5M -6M -46M -12M 50M -48M
depreciationAndAmortization 5M 5M 0 5M 5M 4M 15M 4M 4M 3M 12M 3M 10M 10M
deferredIncomeTax 0 0 0 0 0 0 0 167 000 125 000 0 0 0 85M 2M
stockBasedCompensation 12M 11M 0 10M 10M 9M 36M 9M 9M 9M 29M 7M 28M 23M
changeInWorkingCapital 9M 6M -18M 12M 63 000 -23M -18M -3M -5M -10M -19M -696 000 -5M -7M
accountsReceivables 3M -2M -8M 893 000 -342 000 -3M -10M -3M -3M -3M -9M -228 000 -10M 5M
inventory -3M -824 000 -8M -3M -2M -4M -22M -7M -7M -3M -7M -3M -4M -5M
accountsPayables 360 000 677 000 -2M 4M -2M 2M 6M 1M -121 000 3M 3M 1M 5M -2M
otherWorkingCapital 8M 9M -786 000 10M 4M -18M 7M 6M 4M -7M -5M 1M 5M -5M
otherNonCashItems 535 000 5M 31M 311 000 25M 24M 3M 606 000 449 000 450 000 3M 1M -182M 1M
netCashProvidedByOperatingActivities 27M 22M 12M 20M 8M -22M 4M 2M 3M -4M -22M -2M -14M -20M
investmentsInPropertyPlantAndEquipment -3M -3M 0 -4M -2M -3M -12M -4M -33M -3M -17M -5M -10M -5M
acquisitionsNet 0 0 0 -25 000 25 000 0 0 -30M 0 0 -44M 0 -33M 0
purchasesOfInvestments 0 0 0 0 0 0 0 -16M 0 0 -25M -21M -173M -227M
salesMaturitiesOfInvestments 0 0 0 8M 33M 12M 64M 16M 17M 31M 86M 23M 206M 75M
otherInvestingActivites 0 -5M 25 000 33M 12M 46M 0 0 0
netCashUsedForInvestingActivites -3M -8M 4M 31M 10M 12M -16M 29M -3M
debtRepayment -301 000 -292 000 -269 000 -264 000 -854 999 -248 000 -243 000 -240 000 -225 000
commonStockIssued 0 0 0 0 390 000 815 000 0 0 0
commonStockRepurchased -357 000 -406 000 -7M -63 000 -159 000 -7M -7M -435 000 -299 000 -6M -12M -563 000 -18M -13M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 7M 4M -1000 2M -860 000 815 000 4M 462 000 383 000
netCashUsedProvidedByFinancingActivities 6M 3M -333 000 2M -7M 132 000 3M -6M -405 000
effectOfForexChangesOnCash -26 000 537 000 -424 000 237 000 -57 000 -109 000 -58 000 -166 000 -26 000 25 000 -361 000 -305 000 -372 000 136 000
netChangeInCash 30M 18M 38M 24M 41M -19M 26M 13M -10M 19M 14M -6M 2M 13M
cashAtEndOfPeriod 148M 118M 123M 130M 106M 65M 84M 81M 67M 77M 58M 49M 44M 42M
cashAtBeginningOfPeriod 118M 100M 84M 106M 65M 84M 58M 67M 77M 58M 44M 55M 42M 28M
operatingCashFlow 27M 22M 12M 20M 8M -22M 4M 2M 3M -4M -22M -2M -14M -20M
capitalExpenditure -3M -8M -23M -4M -2M -3M -42M -4M -33M -3M -17M -5M -10M -5M
freeCashFlow 24M 14M -11M 16M 6M -25M -38M -2M -30M -7M -39M -7M -24M -25M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-16 2023-02-22 2022-02-17 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 30M -30M 44M 33M 800 000
netCashProvidedByInvestingActivities 30M 22M 44M 24M -156M
netDebtIssuance -2M -992 000 -899 000 -816 000 -667 000
longTermNetDebtIssuance -2M -992 000 -899 000 -816 000 -667 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -7M -7M -12M -18M 176M
netCommonStockIssuance -7M -7M -12M -18M 176M
commonStockIssuance 0 0 0 0 189M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 5M 8M 6M 11M 14M
netCashProvidedByFinancingActivities -4M -32 000 -7M -8M 189M
incomeTaxesPaid 619 000 395 000 192 000 190 000 217 000
interestPaid 6M 6M 4M 4M 4M

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-29 ET (fiscal 2025 q2)
2025 q1
2025-04-29 ET (fiscal 2025 q1)
2024 q4
2025-02-12 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-07-25 ET (fiscal 2023 q2)
2023 q1
2023-05-02 ET (fiscal 2023 q1)
2022 q4
2023-02-21 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-07-23 20:01 ET
AtriCure Reports Second Quarter 2026 Financial Results
2026-07-02 ET
AtriCure to Announce Second Quarter 2026 Financial Results
2026-05-27 12:00 ET
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
2026-05-05 ET
AtriCure Reports First Quarter 2026 Financial Results
2026-04-28 ET
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
2026-04-14 ET
AtriCure to Announce First Quarter 2026 Financial Results
2026-02-24 ET
AtriCure to Participate in the Citizens Life Sciences Conference
2026-02-17 21:01 ET
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
2026-01-27 ET
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
2026-01-12 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
2025-12-17 ET
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
2025-12-11 ET
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
2025-11-18 ET
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
2025-10-29 20:01 ET
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
2025-10-28 ET
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
2025-10-27 ET
AtriCure to Participate in Upcoming Investor Conferences
2025-10-08 ET
AtriCure to Announce Third Quarter 2025 Financial Results
2025-09-09 ET
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
2025-08-20 ET
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
2025-07-29 ET
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
2025-07-28 ET
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
2025-07-15 ET
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
2025-07-08 ET
AtriCure to Announce Second Quarter 2025 Financial Results
2025-05-23 ET
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-04-29 ET
AtriCure Reports First Quarter 2025 Financial Results
2025-04-10 ET
AtriCure Announces First Use of the AtriClip PRO-Mini® Device
2025-04-08 ET
AtriCure to Announce First Quarter 2025 Financial Results
2025-03-12 ET
AtriCure to Host Analyst & Investor Day on March 26, 2025
2025-02-12 ET
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
2025-01-22 ET
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
2025-01-13 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day
2024-12-23 ET
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-11-20 ET
AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference
2024-11-07 ET
AtriCure to Participate in the Stifel 2024 Healthcare Conference
2024-10-29 20:01 ET
AtriCure Reports Third Quarter 2024 Financial Results
2024-10-28 12:00 ET
AtriCure to Participate in the UBS Global Healthcare Conference
2024-10-15 12:00 ET
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
2024-10-08 12:00 ET
AtriCure to Announce Third Quarter 2024 Financial Results
2024-10-01 12:00 ET
AtriCure Receives CE-Mark for the EnCompass® Clamp
2024-08-27 12:00 ET
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device
2024-08-22 12:00 ET
AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation
2024-07-30 20:01 ET
AtriCure Reports Second Quarter 2024 Financial Results
2024-07-29 12:00 ET
AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference
2024-07-23 12:00 ET
AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China
2024-07-23 12:00 ET
AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China
2024-07-09 12:00 ET
AtriCure to Announce Second Quarter 2024 Financial Results
2024-05-15 12:00 ET
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
2024-05-01 20:01 ET
AtriCure Reports First Quarter 2024 Financial Results
2024-04-30 12:00 ET
AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference
2024-04-18 12:00 ET
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
2024-04-10 12:00 ET
AtriCure to Announce First Quarter 2024 Financial Results
2024-03-26 12:00 ET
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-02-15 21:01 ET
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
2024-01-25 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference
2024-01-08 13:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024
2024-01-04 13:00 ET
AtriCure Appoints Shlomi Nachman to the Board of Directors
2023-12-20 13:00 ET
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-15 13:00 ET
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
2023-11-14 13:00 ET
AtriCure Releases 2023 ESG Report
2023-11-01 20:01 ET
AtriCure Reports Third Quarter 2023 Financial Results
2023-10-31 12:00 ET
AtriCure to Participate in the Stifel 2023 Healthcare Conference
2023-10-11 12:00 ET
AtriCure to Announce Third Quarter 2023 Financial Results
2023-07-25 20:01 ET
AtriCure Reports Second Quarter 2023 Financial Results
2023-07-21 12:00 ET
AtriCure to Participate at Upcoming Investor Conferences
2023-07-03 12:00 ET
AtriCure to Announce Second Quarter 2023 Financial Results
2023-05-02 20:01 ET
AtriCure Reports First Quarter 2023 Financial Results
2023-04-19 12:00 ET
AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast
2023-04-11 12:00 ET
AtriCure to Announce First Quarter 2023 Financial Results
2023-04-03 12:00 ET
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
2023-02-21 21:00 ET
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
2023-02-17 13:00 ET
AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference
2023-01-31 13:00 ET
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
2023-01-24 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
2023-01-09 13:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
2022-12-20 13:00 ET
AtriCure to Participate in the 41st Annual J.P. Morgan Healthcare Conference
2022-12-08 15:30 ET
AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award
2022-11-08 13:00 ET
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
2022-11-01 20:01 ET
AtriCure Reports Third Quarter 2022 Financial Results
2022-10-25 12:00 ET
AtriCure to Participate in Upcoming Investor Conferences
2022-10-11 12:00 ET
AtriCure to Announce Third Quarter 2022 Financial Results
2022-09-06 12:00 ET
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
2022-08-16 12:00 ET
AtriCure to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-02 20:00 ET
AtriCure Reports Second Quarter 2022 Financial Results
2022-07-20 12:00 ET
AtriCure to Participate at Upcoming Investor Conferences
2022-07-12 12:00 ET
AtriCure to Announce Second Quarter 2022 Financial Results
2022-06-07 12:00 ET
AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
2022-06-01 12:00 ET
AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
2022-05-03 20:00 ET
AtriCure Reports First Quarter 2022 Financial Results
2022-04-12 12:00 ET
AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
2022-04-11 12:00 ET
AtriCure to Announce First Quarter 2022 Financial Results
2022-02-15 21:01 ET
AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results
2022-02-08 13:00 ET
AtriCure Publishes Inaugural ESG Report
2022-02-01 13:00 ET
AtriCure to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2022-01-25 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results
2022-01-10 12:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022
2021-12-20 13:00 ET
AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
2021-11-12 13:00 ET
AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
2021-11-03 20:01 ET
AtriCure Reports Third Quarter 2021 Financial Results
2021-10-26 12:00 ET
AtriCure to Participate in Upcoming Investor Conferences
2021-10-05 12:00 ET
AtriCure to Announce Third Quarter 2021 Financial Results
2021-08-31 12:00 ET
AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-04 20:01 ET
AtriCure Reports Second Quarter 2021 Financial Results
2021-07-30 12:00 ET
AtriCure to Participate at the Canaccord 41st Annual Growth Conference
2021-07-07 12:00 ET
AtriCure to Announce Second Quarter 2021 Financial Results
2021-06-15 11:00 ET
AtriCure Names Two New Members to the Board of Directors
2021-04-29 11:00 ET
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
2021-04-27 20:01 ET
AtriCure Reports First Quarter 2021 Financial Results
2021-04-08 12:00 ET
AtriCure Names B. Kristine Johnson Board Chair
2021-04-06 12:00 ET
AtriCure to Announce First Quarter 2021 Financial Results
2021-03-02 21:01 ET
AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference
2021-02-23 21:01 ET
AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
2021-02-10 13:00 ET
AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference
2021-02-02 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results
2021-01-11 12:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020
2021-01-04 13:00 ET
AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy
2020-12-14 13:00 ET
AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference
2020-11-19 13:00 ET
AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-05 21:01 ET
AtriCure Reports Third Quarter 2020 Financial Results
2020-10-26 12:00 ET
AtriCure to Participate in Upcoming Investor Conferences
2020-10-13 12:00 ET
AtriCure to Announce Third Quarter 2020 Financial Results
2020-09-01 12:00 ET
AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference
2020-08-06 20:00 ET
AtriCure Announces Angie Wirick as Chief Financial Officer
2020-07-29 12:00 ET
AtriCure to Participate at Upcoming Investor Conferences
2020-07-28 20:01 ET
AtriCure Reports Second Quarter 2020 Financial Results
2020-07-07 12:00 ET
AtriCure to Announce Second Quarter 2020 Financial Results
2020-05-12 00:10 ET
AtriCure Announces Pricing of Public Offering of Common Stock
2020-05-11 11:16 ET
AtriCure Announces Proposed Public Offering of Common Stock
2020-05-08 12:47 ET
AtriCure Announces Results from CONVERGE IDE Clinical Trial
2020-04-30 12:30 ET
AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting
2020-04-29 20:01 ET
AtriCure Reports First Quarter 2020 Financial Results
2020-04-27 20:02 ET
AtriCure to Participate at Upcoming Investor Conferences
2020-04-15 12:00 ET
AtriCure to Announce First Quarter 2020 Financial Results
2020-04-13 12:00 ET
AtriCure Announces CONVERGE IDE Trial Results Accepted for Late-Breaking Clinical Trial Sessions at Annual Heart Rhythm Society (HRS) Meeting
2020-04-09 12:00 ET
AtriCure Announces Preliminary Financial Results for First Quarter 2020 and Provides COVID-19 Pandemic Update
2020-02-18 21:01 ET
AtriCure Reports Fourth Quarter 2019 and Full Year 2019 Financial Results
2020-02-03 13:00 ET
AtriCure to Participate at the SVB Leerink 9th Annual Global Healthcare Conference
2020-01-28 13:00 ET
AtriCure to Announce Fourth Quarter and Full Year 2019 Financial Results
2020-01-13 13:00 ET
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2019, Provides Financial Outlook for 2020
2020-01-07 13:00 ET
AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol
2019-12-16 13:00 ET
AtriCure to Participate at the 38th Annual JP Morgan Healthcare Conference
2019-12-04 13:00 ET
AtriCure Names Two Industry Veterans to Board of Directors
2019-11-12 13:00 ET
AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference
2019-10-30 20:02 ET
AtriCure Reports Third Quarter 2019 Financial Results
2019-10-21 12:00 ET
AtriCure to Participate in Upcoming Investor Conferences
2019-10-08 12:00 ET
AtriCure to Announce Third Quarter 2019 Financial Results

SEC forms

Show financial reports only

SEC form 10
2026-11-04 00:00 ET
AtriCure published news for 2026 q3
SEC form 8
2026-11-03 00:00 ET
AtriCure reported for 2026 q3
SEC form 8
2026-11-03 00:00 ET
AtriCure published news for 2026 q3
SEC form 10
2026-07-27 13:07 ET
AtriCure reported for 2026 q2
SEC form 8
2026-07-23 20:00 ET
AtriCure reported for 2026 q2
SEC form 8
2026-07-23 20:00 ET
AtriCure published news for 2026 q2
SEC form 10
2026-05-06 16:31 ET
AtriCure reported for 2026 q1
SEC form 8
2026-05-06 01:01 ET
AtriCure published news for 2026 q1
SEC form 8
2026-05-06 01:01 ET
AtriCure reported for 2026 q1
SEC form 8
2026-05-05 20:00 ET
AtriCure published news for 2026 q1
SEC form 8
2026-05-05 20:00 ET
AtriCure published news for 2026 q1
SEC form 10
2026-02-19 17:39 ET
AtriCure published news for 2025 q4
SEC form 8
2026-02-17 16:00 ET
AtriCure published news for 2025 q4
SEC form 8
2026-02-17 16:00 ET
AtriCure reported for 2025 q4
SEC form 8
2025-10-29 21:18 ET
AtriCure published news for 2025 q3
SEC form 8
2025-10-29 21:18 ET
AtriCure reported for 2025 q3
SEC form 8
2025-10-29 20:00 ET
AtriCure published news for 2025 q3
SEC form 8
2025-10-29 20:00 ET
AtriCure published news for 2025 q3
SEC form 8
2025-07-29 20:00 ET
AtriCure reported for 2025 q2
SEC form 8
2025-07-29 20:00 ET
AtriCure published news for 2025 q2
SEC form 10
2025-04-30 00:00 ET
AtriCure published news for 2025 q1
SEC form 8
2025-04-29 00:00 ET
AtriCure reported for 2025 q1
SEC form 8
2025-04-29 00:00 ET
AtriCure published news for 2025 q1
SEC form 10
2025-02-14 00:00 ET
AtriCure published news for 2024 q4
SEC form 8
2025-02-12 16:00 ET
AtriCure published news for 2024 q4
SEC form 8
2025-02-12 16:00 ET
AtriCure reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
AtriCure published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
AtriCure published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
AtriCure published news for 2024 q4
SEC form 10
2024-10-30 11:49 ET
AtriCure reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
AtriCure reported for 2024 q3
SEC form 8
2024-10-29 16:01 ET
AtriCure published news for 2024 q3
SEC form 8
2024-10-29 16:01 ET
AtriCure reported for 2024 q3
SEC form 10
2024-07-31 11:39 ET
AtriCure published news for 2024 q2
SEC form 10
2024-07-31 00:00 ET
AtriCure published news for 2024 q2
SEC form 8
2024-07-30 16:00 ET
AtriCure published news for 2024 q2
SEC form 8
2024-07-30 16:00 ET
AtriCure reported for 2024 q2
SEC form 10
2024-05-02 11:15 ET
AtriCure published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
AtriCure published news for 2024 q1
SEC form 8
2024-05-01 16:00 ET
AtriCure published news for 2024 q1
SEC form 8
2024-05-01 16:00 ET
AtriCure reported for 2024 q1
SEC form 10
2024-02-16 00:00 ET
AtriCure published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
AtriCure published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
AtriCure reported for 2023 q4
SEC form 10
2023-11-02 12:17 ET
AtriCure published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
AtriCure published news for 2023 q3
SEC form 8
2023-11-01 16:01 ET
AtriCure reported for 2023 q3
SEC form 10
2023-07-26 13:42 ET
AtriCure published news for 2023 q2
SEC form 10
2023-07-26 00:00 ET
AtriCure published news for 2023 q2
SEC form 6
2023-07-25 16:00 ET
AtriCure reported for 2023 q2
SEC form 8
2023-07-25 00:00 ET
AtriCure published news for 2023 q2
SEC form 6
2023-05-26 11:51 ET
AtriCure published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
AtriCure published news for 2023 q1
SEC form 8
2023-05-02 00:00 ET
AtriCure published news for 2023 q1
SEC form 10
2023-02-22 00:00 ET
AtriCure reported for 2022 q4
SEC form 8
2023-02-21 00:00 ET
AtriCure reported for 2022 q4
SEC form 8
2023-01-09 00:00 ET
AtriCure published news for 2022 q4
SEC form 10
2022-11-02 00:00 ET
AtriCure reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
AtriCure reported for 2022 q3
SEC form 10
2022-08-03 00:00 ET
AtriCure reported for 2022 q2
SEC form 8
2022-08-02 00:00 ET
AtriCure reported for 2022 q2
SEC form 10
2022-05-04 00:00 ET
AtriCure reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
AtriCure reported for 2022 q1
SEC form 10
2022-02-17 00:00 ET
AtriCure published news for 2021 q4
SEC form 8
2022-02-15 00:00 ET
AtriCure published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
AtriCure published news for 2021 q4
SEC form 10
2021-11-04 00:00 ET
AtriCure published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
AtriCure published news for 2021 q3
SEC form 10
2021-08-05 00:00 ET
AtriCure published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
AtriCure published news for 2021 q2
SEC form 10
2021-04-28 00:00 ET
AtriCure published news for 2021 q1
SEC form 8
2021-04-27 00:00 ET
AtriCure published news for 2021 q1